Market revenue in 2023 | USD 8.5 million |
Market revenue in 2030 | USD 24.2 million |
Growth rate | 16.1% (CAGR from 2023 to 2030) |
Largest segment | Immunotherapy |
Fastest growing segment | Immunotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 60% in 2023. Horizon Databook has segmented the UAE head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2018 to 2030.
The UAE market is rapidly growing. Although the UAE currently imports the majority of its pharmaceuticals, this scenario is changing, and some international pharmaceutical giants have partnered with UAE companies to manufacture products locally.
The COVID-19 pandemic has increased the country’s focus on investing in life sciences domestically and internationally. Moreover, initiatives to enhance public health in the UAE are taken, which is further anticipated to propel the market.
Moreover, the UAE is one of the leading contributors to the cancer burden in the MEA. According to the UAE National Cancer Registry, in 2019, the country reported over 4,633 new cancer cases, of which 4,381 were malignant and 252 were in situ.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE head and neck cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into UAE head and neck cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account